Clinical trials: Diabete Type 2
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Michigan Men's Diabetes Project 2
The Michigan Men's Diabetes Project 2 (MenD 2) is an 18-month pilot randomized clinical trial. We are looking to recruit 60 Black men with type 2 diabetes (need to have diagnosis for at least 6 months) that are over the age of…
- Trial name
- MenD 2 (NCT05370781)
- Testing
- Peer Led Diabetes Self-Management Support, Diabetes Self-Management Education
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Michigan
Diabetes Mellitus, Type 2
Insulin Glulisine in Type 2 Diabetic Patients
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled…
- Trial name
- Basal Plus (NCT00360698)
- Testing
- Insulin Glargine, Glimepiride, Insulin Glulisine
- Where
- 3 sites in United States, Russia and 1 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
The objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.
- Trial name
- NCT00935532
- Testing
- exenatide once weekly, insulin glargine
- Where
- 22 sites in Japan
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Embedded Primary Care MultiDisciplinary Diabetes Clinic
The purpose of this study is to improve diabetes management for patients at Midtown General Internal Medicine Clinic (Aim 1). The clinic offers dedicated diabetes care on certain days with trained providers able to offer…
- Trial name
- NCT06015685
- Testing
- Embedded Clinic
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Emory University
Prediabetes
Diabetes Prevention Using SMS Technology
Type 2 diabetes is a major healthcare problem in the developed and developing world. Recent clinical trials have demonstrated that it may be prevented by lifestyle intervention focused on diet and physical activity.
- Trial name
- NCT01795833
- Testing
- Short text messages
- Where
- United Kingdom
- Volunteers
- 2,062 people
- Sponsor
- Imperial College London
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
- Trial name
- SUSTAIN 7 (NCT02648204)
- Testing
- semaglutide, Dulaglutide
- Where
- 209 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,201 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes
The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT02588950
- Testing
- U-500R
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
Usability and Acceptability Study of the P-STEP Mobile Application
Assess the usability and acceptance of the P-STEP app, through allowing participants with specific chronic conditions to pilot the app for 12-weeks.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Coronary Heart Disease
- Trial name
- NCT05830318
- Testing
- P-STEP Mobile Application
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- University of Leicester
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01572740
- Testing
- liraglutide, insulin
- Where
- 23 sites in Japan
- Volunteers
- 257 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing…
- Trial name
- BEGIN™ (NCT01068665)
- Testing
- insulin degludec, insulin glargine
- Where
- 116 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Obesity, Uric Acid Stones
Phentermine/Topiramate for Uric Acid Stones
The investigator proposes an 18 month, feasibility pilot study, randomizing obese and diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO) UAN to either phentermine/topiramate or a…
- Conditions
- Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
- Trial name
- NCT04621929
- Testing
- Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information
- Trial name
- AVANDAMETPMS (NCT01294553)
- Testing
- Administration of rosiglitazone/metformin
- Volunteers
- 717 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Evaluation of the Accuracy of an Implanted Glucose Sensor
The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The…
- Trial name
- PRECISEII (NCT02647905)
- Testing
- Continuous Glucose Monitoring System
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 2
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine)…
- Trial name
- NCT02981966
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Effect on Weight Loss of Exenatide Versus Placebo
This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT00375492
- Testing
- exenatide
- Where
- 10 sites in United States
- Volunteers
- 196 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.